Company intelligence / Profile preview

Sagimet Biotech

San Mateo, California, United States

Ownership: Private
Employees: ~35
Development stage: Other

Overview

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics that target dysfunctional metabolic pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily fatty acid synthase (FASN) inhibitor currently in Phase 3 development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). By inhibiting FASN, Sagimet aims to reduce liver fat, inflammation, and fibrosis. Beyond MASH, the company is exploring its FASN inhibitor platform for other indications, including acne and certain types of cancer.

Therapeutic areas: OncologyDermatologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Partnerships

Ascletis Pharma

Beyond the preview

Go deeper on Sagimet Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sagimet Biotech.

Explore the full profile